Press Releases and Publications
Press Releases
Soraprazan Press Release - 2020-10 14: Katairo announces “Enrolment Completion” in STARTT Study of Remofuscin - 2020-10 14107 KB
Soraprazan Press Release: Katairo announces “Enrolment Completion” in STARTT Study of Remofuscin STARTT: Stargardt Remofuscin® Treatment Trial: A multi-national, multi-center, doublemasked, placebo-controlled, proof of concept trial to evaluate the safety and efficacy of oral soraprazan in adults with Stargardt disease.
Soraprazan Press Release - 2019-06-26107 KB
Soraprazan Press Release: Katairo Announces “First Patient Treated” in STARTT Study of Remofuscin®. STARTT: Stargardt Remofuscin® Treatment Trial: A multi-national, multi-center, doublemasked, placebo-controlled, proof of concept trial to evaluate the safety and efficacy of oral soraprazan in adults with Stargardt disease.
Soraprazan Press Release - 2018-02-0977 KB
Soraprazan Press Release: EU funding for Proof of Concept clinical study in Stargardt’s disease - Katairo received 6 million euros from the European Commission’s H2020 program